110.50Open110.50Pre Close0 Volume1 Open Interest120.00Strike Price0.00Turnover109.75%IV-9.16%PremiumDec 20, 2024Expiry Date133.74Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9981Delta0.0001Gamma1.89Leverage Ratio-0.0227Theta0.0732Rho1.89Eff Leverage0.0038Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet